Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Lung Cancer Video Library - Spanish Language: Video #42 Stage IIIA N2 Non-Small Cell Lung Cancer
Author
Denise Brock
 

 

We are pleased to continue this series of informational videos for our Spanish speaking community.  GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance.  In this 42nd video for the Spanish lung cancer video library, Dr. Santana-Davila joined GRACE to discuss Stage IIIA N2 Non-Small Cell Lung Cancer.


 

 

Tratamiento del Paciente que Tiene Estadio Tres, cuando los Ganglios del Mismo Lado del Mediastino están Involucrados

Stage IIIA N2 Non-Small Cell Lung Cancer

 

Assistant Professor of Medicine
University of Washington Seattle Cancer Care Alliance
Seattle, Washington

 

Spanish TRANSCRIPT

Cuando esto ocurre, el tratamiento varía mucho dependiendo de la institución que este viendo al paciente. En la Universidad de Washington lo que hacemos es que si hay un solo ganglio linfático involucrado preferimos dar quimioterapia. En un principio de 3 a 4 ciclos, después repetimos los estudios de imágenes y si el cancer no ha avanzado se lleva al paciente a cirugía donde lo primero que se hace es ver cuáles de los ganglios del mediastino están involucrados. Si el cancer no ha avanzado, se trata posteriormente con una lobectomía (remover el lóbulo del pulmón). Después, si los ganglios del mediastino se vieron afectados, entonces el paciente se hace candidato para ser tratado con radioterapia para erradicar esos ganglios del mediastino.

Cuando el cancer de pulmón está en más de un ganglio en el mediastino, lo que hacemos es quimioterapia y radiación al mismo tiempo. Son de cuatro a seis semanas de radiación con quimioterapia, dependiendo de que quimioterapia se elige, se puede dar una por semana o dar dos ciclos de quimioterapia en toda la radiación. La quimioterapia que se escoge depende mucho de la discusión entre doctor y paciente para ver qué efectos adversos se prefieren y cuáles son los riesgos y beneficios. 


  

English TRANSCRIPT

When the patient is in stage three, there are many options for the treatment depending on the institution the patient is being treated. In the University of Washington, if there is only one lymph node affected, we prefer to give chemotherapy. At first, we’ll give three to four cycles then we’ll do again imaging studies to see if the cancer has not spread. If the cancer has advanced to other parts, the patient will go into surgery to see which lymph nodes from the mediastinum are involved. However, if the cancer has not spread, the procedure used will be a lobectomy (remove one of the lobes of the lung).  Then, if the lymph nodes of the mediastinum are affected, the patient will be candidate to be treated with radiotherapy. 

When the lung cancer is in more lymph nodes in the mediastinum, we’ll then use chemotherapy and radiation at the same time. This consists of four to six weeks of radiation and chemotherapy. Depending on the type of chemotherapy selected, the treatment could be one cycle per week or two chemotherapy cycles in all the radiation process. The type of chemotherapy selected depends on the doctor-patient discussion about the side effects, risks and benefits.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on